Mirror images: Is levalbuterol the fairest of them all?

Journal of Pediatrics

Volumn 143, Issue 6, 2003, Pages 702-704

  Kattan, Meyer ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LEVALBUTEROL; SALBUTAMOL;

ASTHMA; CLINICAL TRIAL; DRUG POTENCY; EDITORIAL; EMERGENCY WARD; ENANTIOMER; HOSPITALIZATION; HUMAN; ISOMER; ISOMERISM; PRIORITY JOURNAL; TACHYCARDIA; TREMOR;

EID: 0344233253     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2003.10.018     Document Type: Editorial

References (21)

1. 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997;52:849-52.
2. Lotvall J, Palmqvist M, Arvidsson P, Maloney A, Ventresca GP, Ward J. The therapeutic ratio of R-albuterol is comparable with that of RS-albuterol in asthmatic patients. J Allergy Clin Immunol 2001;108: 726-31.
3. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)-and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol 2002;109:449-54.
4. 2-selective sympathomimetics. Pulmonol Pharmacol 1994;7:367-76.
5. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615-21.
6. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001;108:938-45.
7. 2-agonists: comparison of the enantiomers of salbutamol with racemic salbutamol and placebo. J Allergy Clin Immunol 1999;103:1049-53.
8. Cockcroft DW, Swystun VA. Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine. Thorax 1997;52:845-8.
9. Ind PW. Salbutamol enantiomers: early clinical evidence in humans. Thorax 1997;52:839-40.
10. Ahrens R, Weinberger M. Levalbuterol and racemic albuterol: are there therapeutic differences? J Allergy Clin Immunol 2001;108:681-4.
11. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Heart, Lung, and Blood Institute; 1997. Report No.: NIH publication no. 97-4051.
12. Ben-Zvi Z, Lam C, Spohn WA, Gribetz I, Mulvihill MN, Kattan M. An evaluation of repeated injections of epinephrine for the initial treatment of acute asthma. Am Rev Respir Dis 1983;127:101-5.
13. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbutreol for treatment of acute asthma. J Pediatr 2003;143:731-6.
14. Kattan M, Mitchell H, Eggleston P, Gergen P, Crain E, Redline S, et al. Characteristics of inner-city children with asthma: the National Cooperative Inner-City Asthma Study. Pediatr Pulmonol 1997;24:253-62.
15. Fischl MA, Pitchenik A, Gardner LB. An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med 1981;305:783-9.
16. Asmus MJ, Hendeles L. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? Pharmacotherapy 2000;20:123-9.
17. Newhouse MT. Asthma therapy with aerosols: are nebulizers obsolete? A continuing controversy. J Pediatr 1999;135:5-8.
18. Schuh S, Johnson DW, Stephens D, Callahan S, Winders P, Canny GJ. Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr 1999;135:22-7.
19. Chou KJ, Cunningham SJ, Crain EF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med 1995;149:201-5.
20. Browne GJ, Wilkins BH. Use of intravenous salbutamol in acute severe asthma. Anaesthesia 2003;58:729-32.
21. Pear R. Congress weighs drug comparisons. New York Times, August 24, 2003.